trending Market Intelligence /marketintelligence/en/news-insights/trending/alomvnolc3ipbhf1hw6dag2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

IntelGenx Technologies prices offering of units

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


IntelGenx Technologies prices offering of units

IntelGenx Technologies Corp. priced an agency offering of 17,144,314 units at 70 cents each.

The Canadian drug delivery company expects to raise gross proceeds of about $12 million from the offering.

Each unit comprises 1 common share and half a warrant to buy 1 common share for $1.

The offering is being made on a best-efforts basis in the U.S. and the Canadian provinces of British Columbia, Alberta, Manitoba, Ontario and Quebec, and it is expected to close on or about Oct. 22.

Net proceeds will go toward IntelGenx Technologies' clinical development, regulatory activity and working capital.

The company applied to list the offered shares and warrants on the TSX Venture Exchange.

H.C. Wainwright & Co. is acting as exclusive agent for the units offered in the U.S. Echelon Wealth Partners Inc. is acting as exclusive placement agent for the units offered in Canada. Echelon has a 30-day overallotment option to buy an equivalent of up to 15% of the shares and warrants being offered.

IntelGenx Technologies develops and makes pharmaceutical oral films based on its proprietary VersaFilm technology platform.